• ProKidney’s third-quarter 2026 net loss available to Class A common stockholders more than doubled year over year to $35.59 million.
• Revenue fell 20% year over year to $174,000, while research and development expenses climbed 52% to $40.85 million.
• Cash, cash equivalents and marketable securities totaled $141.9 million at September 30, supporting operations into mid-2027.
• Pivotal Phase 3 PROACT 1 eGFR-slope results remain scheduled for Q2 2027, with full enrollment expected in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prokidney Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121610PRIMZONEFULLFEED9876823) on November 12, 2026, and is solely responsible for the information contained therein.